Here are four notes:
1. Five analysts have an “outperform” rating on the shares and two analysts gave the shares a “hold” rating.
2. No analysts have an “underperform” or “sell” rating on LDR shares.
3. On Feb. 18, BMO Capital Markets reiterated LDR’s “market perform” rating.
4. BMO analysts had a price target of $23 on LDR shares on Feb. 18.
More articles on devices:
Globus Medical 2015 net income hits $112.8M: 6 things to know
Neurosurgery device developer addresses market demand for new brain technologies: 6 notes
CoNextions Medical to introduce tendon repair device at AAOS meeting: 3 quick notes
At the Becker's 23rd Annual Spine, Orthopedic and Pain Management-Driven ASC + The Future of Spine Conference, taking place June 11-13 in Chicago, spine surgeons, orthopedic leaders and ASC executives will come together to explore minimally invasive techniques, ASC growth strategies and innovations shaping the future of outpatient spine care. Apply for complimentary registration now.
